LALPATHLAB Dr. Lal Path Labs Q3 FY26 results (Oct–Dec 2025) and concall
Dr Lal Pathlabs delivered steady double-digit revenue growth in Q3 FY26, despite a slowdown in patient volumes caused by a weak seasonal fever cycle. The company successfully expanded its realization per patient through a better test mix and the scaling of its Swasthfit wellness portfolio. While a one-time labour code provision impacted reported profits, underlying operating margins remained resilient, and the company is pivoting toward personalized preventive care with the launch of its 'Sovaaka' platform.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.6%, net profit down 7.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 | 731 +11% | 660 +11% |
| EBITDA | 202 | 154 | 169 | 192 | 224 +11% | 179 +16% |
| Net profit | 131 | 98 | 156 | 134 | 152 +16% | 91 −7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
